260 related articles for article (PubMed ID: 17601878)
21. Structural variability in the glucuronoxylomannan of Cryptococcus neoformans serotype A isolates determined by 13C NMR spectroscopy.
Turner SH; Cherniak R; Reiss E; Kwon-Chung KJ
Carbohydr Res; 1992 Sep; 233():205-18. PubMed ID: 1446309
[TBL] [Abstract][Full Text] [Related]
22. A Paracoccidioides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan.
Albuquerque PC; Cordero RJ; Fonseca FL; Peres da Silva R; Ramos CL; Miranda KR; Casadevall A; Puccia R; Nosanchuk JD; Nimrichter L; Guimaraes AJ; Rodrigues ML
Fungal Genet Biol; 2012 Nov; 49(11):943-54. PubMed ID: 23010152
[TBL] [Abstract][Full Text] [Related]
23. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
Todaro-Luck F; Reiss E; Cherniak R; Kaufman L
Infect Immun; 1989 Dec; 57(12):3882-7. PubMed ID: 2680986
[TBL] [Abstract][Full Text] [Related]
24. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils.
Monari C; Retini C; Casadevall A; Netski D; Bistoni F; Kozel TR; Vecchiarelli A
Eur J Immunol; 2003 Apr; 33(4):1041-51. PubMed ID: 12672070
[TBL] [Abstract][Full Text] [Related]
25. Finite-element model of interaction between fungal polysaccharide and monoclonal antibody in the capsule of Cryptococcus neoformans.
Rakesh V; Schweitzer AD; Zaragoza O; Bryan R; Wong K; Datta A; Casadevall A; Dadachova E
J Phys Chem B; 2008 Jul; 112(29):8514-22. PubMed ID: 18588334
[TBL] [Abstract][Full Text] [Related]
26.
Gonçalves DS; Rodriguez de La Noval C; Ferreira MDS; Honorato L; Araújo GRS; Frases S; Pizzini CV; Nosanchuk JD; Cordero RJB; Rodrigues ML; Peralta JM; Nimrichter L; Guimarães AJ
Front Cell Infect Microbiol; 2020; 10():565571. PubMed ID: 33585262
[TBL] [Abstract][Full Text] [Related]
27. Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.
De Jesus M; Nicola AM; Rodrigues ML; Janbon G; Casadevall A
Eukaryot Cell; 2009 Jan; 8(1):96-103. PubMed ID: 18952901
[TBL] [Abstract][Full Text] [Related]
28. Parallel beta-helix proteins required for accurate capsule polysaccharide synthesis and virulence in the yeast Cryptococcus neoformans.
Liu OW; Kelly MJ; Chow ED; Madhani HD
Eukaryot Cell; 2007 Apr; 6(4):630-40. PubMed ID: 17337638
[TBL] [Abstract][Full Text] [Related]
29. Protein-polysaccharide interactions. A monoclonal antibody specific for the capsular polysaccharide of Cryptococcus neoformans.
Otteson EW; Welch WH; Kozel TR
J Biol Chem; 1994 Jan; 269(3):1858-64. PubMed ID: 8294434
[TBL] [Abstract][Full Text] [Related]
30. Production of extracellular polysaccharides by CAP mutants of Cryptococcus neoformans.
Grijpstra J; Gerwig GJ; Wösten H; Kamerling JP; de Cock H
Eukaryot Cell; 2009 Aug; 8(8):1165-73. PubMed ID: 19542308
[TBL] [Abstract][Full Text] [Related]
31. Structure of the 13C-enriched O-deacetylated glucuronoxylomannan of Cryptococcus neoformans serotype A determined by NMR spectroscopy.
Sheng S; Cherniak R
Carbohydr Res; 1997 Jun; 301(1-2):33-40. PubMed ID: 9228737
[TBL] [Abstract][Full Text] [Related]
32. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.
Zhang H; Zhong Z; Pirofski LA
Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446
[TBL] [Abstract][Full Text] [Related]
33. Evasion of Innate Immune Responses by the Highly Virulent Cryptococcus gattii by Altering Capsule Glucuronoxylomannan Structure.
Urai M; Kaneko Y; Ueno K; Okubo Y; Aizawa T; Fukazawa H; Sugita T; Ohno H; Shibuya K; Kinjo Y; Miyazaki Y
Front Cell Infect Microbiol; 2015; 5():101. PubMed ID: 26779451
[TBL] [Abstract][Full Text] [Related]
34. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens.
Pirofski LA
Trends Microbiol; 2001 Sep; 9(9):445-51. PubMed ID: 11553457
[TBL] [Abstract][Full Text] [Related]
35. Polysaccharide diversity in VNI isolates of Cryptococcus neoformans from Roraima, Northern Brazil.
Dal Pupo HD; Sena BAG; Reis FCG; Machado L; Fortes ST; de Almeida Junior JN; Godinho RMC; Rodrigues ML
Fungal Biol; 2019 Oct; 123(10):699-708. PubMed ID: 31542188
[TBL] [Abstract][Full Text] [Related]
36. The Overlooked Glycan Components of the Cryptococcus Capsule.
Fonseca FL; Reis FCG; Sena BAG; Jozefowicz LJ; Kmetzsch L; Rodrigues ML
Curr Top Microbiol Immunol; 2019; 422():31-43. PubMed ID: 30203395
[TBL] [Abstract][Full Text] [Related]
37. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
Martinez LR; Moussai D; Casadevall A
Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
[TBL] [Abstract][Full Text] [Related]
38. Glucuronoxylomannan of Cryptococcus neoformans serotype B: structural analysis by gas-liquid chromatography-mass spectrometry and 13C-nuclear magnetic resonance spectroscopy.
Turner SH; Cherniak R
Carbohydr Res; 1991 Apr; 211(1):103-16. PubMed ID: 1773425
[TBL] [Abstract][Full Text] [Related]
39. Structural studies of the capsular polysaccharide of a non-neoformans Cryptococcus species identified as C. laurentii, which was reclassified as Cryptococcus flavescens, from a patient with AIDS.
Ikeda R; Maeda T
Carbohydr Res; 2004 Feb; 339(3):503-9. PubMed ID: 15013387
[TBL] [Abstract][Full Text] [Related]
40. Regulated Release of Cryptococcal Polysaccharide Drives Virulence and Suppresses Immune Cell Infiltration into the Central Nervous System.
Denham ST; Verma S; Reynolds RC; Worne CL; Daugherty JM; Lane TE; Brown JCS
Infect Immun; 2018 Mar; 86(3):. PubMed ID: 29203547
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
